Aegis Capital Corp. in an IPO of Akers Biosciences
Blank Rome represented Aegis Capital Corp. in a $15 million IPO of Akers Biosciences, Inc., a company that develops, manufactures, and supplies rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician. The transaction closed in January 2014.